Liposomal iNKT Agonist PORT-2

**Semantic type:** Pharmacologic Substance

**Definition:** A liposomal formulation of IMM60, a synthetically derived small molecule agonist of natural killer T-cells (NKTs) expressing an invariant (alpha, beta) T-cell receptor (iNKTs), with potential immunomodulating and antineoplastic activities. Upon intravenous administration of liposomal iNKT agonist PORT-2, IMM60 targets and binds to the T-cell receptor on iNKTs, thereby activating iNKTs. In turn, iNKTs recognize CD1d-restricted lipid ligands, which are expressed on certain tumor cells, and secrete large amounts of various pro-inflammatory cytokines, including interferon-gamma (IFNg). This may activate the immune system against tumor cells. Additionally, iNKTs directly target and lyse CD1d-expressing tumor cells.

**Synonyms:** - IMM60 Liposome Formulation PORT-2 - Liposomal Invariant Natural Killer T-cell Agonist PORT-2 - PORT 2 - PORT-2 - PORT2